26 April 2023 
EMA/CHMP/168258/2023 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Bimzelx 
bimekizumab 
On 26 April 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Bimzelx. The marketing authorisation holder for this medicinal product is UCB Pharma S.A. 
The CHMP adopted a new indication to include treatment of adults with active non-radiographic axial 
spondyloarthritis with objective signs of inflammation who have responded inadequately or are intolerant 
to non-steroidal anti-inflammatory drugs (NSAIDs) and of adults with active ankylosing spondylitis who 
have responded inadequately or are intolerant to conventional therapy. 
For information, the full indications for Bimzelx will be as follows:2 
Plaque psoriasis 
Bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are 
candidates for systemic therapy. 
Axial spondyloarthritis 
Non-radiographic axial spondyloarthritis (nr-axSpA) 
Bimzelx is indicated for the treatment of adults with active non-radiographic axial 
spondyloarthritis with objective signs of inflammation as indicated by elevated C-
reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have 
responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs 
(NSAIDs). 
Ankylosing spondylitis (AS, radiographic axial spondyloarthritis) 
Bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who 
have responded inadequately or are intolerant to conventional therapy. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Bimzelx  
EMA/CHMP/168258/2023 
Page 2/2 
 
 
 
 
